SOLV vs ISRG vs ABT Stock Comparison

Solventum, Intuitive Surgical and Abbott Laboratories Prices as of Nov 13, 2026 Peers: Industry group
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.31B
P/E
98.1x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
2 wins
ISRG Intuitive Surgical Inc
$443.59 +5.6% 1M -21.6% 1Y
Market cap
$154.57B
P/E
52.3x
Revenue (TTM)
$11.58B
Div. yield
–
Medical Devices Healthcare
4 wins
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$188.33B
P/E
40.1x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
5 wins

Head to Head

11 decided of 12

Abbott Laboratories leads on 5 of the 12 questions below (Abbott Laboratories 5, Intuitive Surgical 4, Solventum 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionSOLVISRGABTLeader
Larger companyMarket capitalisation $15.31B $154.57B $188.33B ABT
Cheaper on earningsLower P/E, profitable companies only 98.1x 52.3x 40.1x ABT
Cheaper on forward earningsLower price / next fiscal year consensus EPS 12.8x 38.5x 19.1x SOLV
Faster revenue growthRevenue growth, trailing twelve months -2.8% +20.5% +10.0% ISRG
More profitableNet margin, trailing twelve months 1.9% 25.5% 9.7% ISRG
Better return on capitalReturn on invested capital 4.2% — 5.7% ABT
Less leveragedLower net debt / EBITDA 4.7x — 2.5x ABT
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.02% –
Better 1-year returnPrice return, last 12 months +18.4% -21.6% -16.0% SOLV
Better 5-year returnAnnualised price return, 5 years — +4.6%/yr -3.3%/yr ISRG
Less volatileAnnualised volatility, 1 year 30.1% 36.1% 28.5% ABT
Higher overall scoreMean of the five percentile scores vs peers 51/100 81/100 56/100 ISRG

Percentile Scorecard

SOLVISRGABT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisSOLVISRGABT
Valuation 70 #74 of 243 52 #118 of 243 74 #65 of 243
Growth 3 #221 of 228 81 #45 of 228 26 #168 of 228
Profitability 71 #66 of 222 97 #7 of 222 82 #41 of 222
Financial Health 15 #210 of 248 81 #47 of 248 33 #167 of 248
Shareholder Returns 94 #10 of 158 95 #9 of 158 65 #56 of 158
Overall 51 81 56
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics
  • ISRG ranked among 252 companies in Medical Devices and Diagnostics
  • ABT ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodSOLVISRGABTSPY
1 month +2.0%+5.6%+5.4% -2.0%
3 months +0.5%+12.4%-2.4% -2.8%
6 months +19.9%+5.3%+28.5% +2.0%
Year to date +12.4%-21.7%-13.4% +10.6%
1 year +18.4%-21.6%-16.0% +12.2%
3 years —+52.1%+11.8% +68.1%
3 years, per year —+15.0%+3.8% +18.9%
5 years —+25.0%-15.5% +61.4%
5 years, per year —+4.6%-3.3% +10.1%
10 years —+542.1%+170.4% +248.5%
10 years, per year —+20.4%+10.5% +13.3%

Risk

MeasureSOLVISRGABTSPY
Volatility, 1Y 30.1%36.1%28.5% 13.6%
Downside volatility, 1Y 29.3%38.4%27.8% 13.9%
Beta vs S&P 500, 1Y 0.610.920.07 1.00
Return / volatility, 1Y 0.61-0.60-0.56 0.90
Max drawdown, 5Y -40.0%-49.9%-41.6% -25.4%
From 52-week high -3.7%-25.2%-16.9% -3.2%
52-week high $92.45$592.85$130.59 $779.14
52-week low $62.49$332.02$82.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleSOLVISRGABT
P/E now vs peer median 97.5xmedian 26.5x 52.4xmedian 26.5x 40.0xmedian 26.5x
P/S now vs peer median 1.9xmedian 2.7x 13.3xmedian 2.7x 3.9xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 36.6xmedian 18.4x 20.3xmedian 18.4x
P/FCF now vs peer median 156.0xmedian 25.4x 42.7xmedian 25.4x 27.8xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 9.5xmedian 2.5x 3.6xmedian 2.5x
PEG now vs peer median —median 0.98 2.04median 0.98 -13.92median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsSOLVISRGABT
Revenue $8.16B $11.58B $48.23B
Gross profit $4.47B $7.78B $27.46B
Operating income $454.00M $3.28B $6.65B
Net income $156.00M $2.97B $4.70B
Free cash flow – $3.60B $6.76B
R&D $723.00M $1.49B $3.31B
EPS (diluted) $0.91 $8.41 $2.70
Cash & equivalents $451.00M $2.98B $4.05B
Total debt $5.07B – $31.16B
Shares (diluted) 170.80M 351.60M 1.74B
Enterprise value $13.02B $134.85B $162.19B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricSOLVISRGABT
P/E 97.5x 52.4x 40.0x
P/FCF 156.0x 42.7x 27.8x
P/Operating cash flow 48.8x 37.6x 21.2x
P/S 1.9x 13.3x 3.9x
P/B 3.1x 9.5x 3.6x
P/Tangible book 6.1x 10.3x 5.9x
EV/EBITDA 20.3x 36.6x 20.3x
EV/EBIT 43.5x 45.6x 32.3x
EV/Revenue 2.4x 12.9x 4.5x
EV/FCF – 41.6x 31.8x
EV/Operating cash flow 63.7x 36.6x 24.3x
PEG (3Y EPS CAGR) – 2.04 -13.92

Growth

14 metrics
MetricSOLVISRGABT
Revenue growth (1Y) -2.8% 20.5% 10.0%
Revenue CAGR (3Y) – 19.1% 6.5%
Gross profit growth (1Y) -1.6% 21.9% 12.1%
Gross profit CAGR (3Y) – 19.5% 7.8%
Operating income growth (1Y) -79.3% 16.6% -13.8%
Operating income CAGR (3Y) – 24.8% 3.5%
Net income growth (1Y) -89.8% 7.5% -66.4%
Net income CAGR (3Y) – 24.4% -3.1%
EPS growth (1Y) -89.5% 10.8% -66.1%
EPS CAGR (3Y) – 25.7% -2.9%
Operating cash flow growth (1Y) -37.1% 38.1% -2.9%
Operating cash flow CAGR (3Y) – 26.4% 10.6%
Free cash flow growth (1Y) – 58.4% -2.3%
Free cash flow CAGR (3Y) – 42.0% 14.6%

Profitability

14 metrics
MetricSOLVISRGABT
Gross margin 54.8% 67.2% 56.9%
EBITDA margin 11.9% 35.3% 21.9%
Operating margin 5.6% 28.4% 13.8%
Pretax margin 2.1% 31.3% 13.6%
Net margin 1.9% 25.5% 9.7%
FCF margin – 31.1% 14.0%
Operating cash flow margin 3.8% 35.3% 18.4%
Return on equity 3.3% 17.3% 9.1%
Return on assets 1.1% 14.8% 4.3%
Return on invested capital 4.2% – 5.7%
Return on capital employed 4.3% 18.7% 7.2%
Asset turnover 0.6x 0.6x 0.4x
Cash conversion (OCF / net income) 2.0x 1.4x 1.9x
Stock comp / revenue 2.1% 7.2% 1.5%

Financial Health

11 metrics
MetricSOLVISRGABT
Debt / assets 35.8% – 28.8%
Debt / equity 1.1x – 0.6x
Net debt / EBITDA 4.7x – 2.5x
Debt / FCF – – 4.6x
Liabilities / assets 66.1% 16.7% 52.3%
Equity / assets 33.9% 83.3% 47.7%
Interest coverage – – 6.7x
Current ratio 1.0x 3.3x 1.5x
Quick ratio 0.5x 2.3x 0.8x
Cash ratio 0.1x 1.6x 0.3x
Altman Z-score 1.85 30.40 3.36

Shareholder Returns

7 metrics
MetricSOLVISRGABT
Dividend yield – – 2.3%
Net buyback yield 2.7% 2.8% 0.7%
Shareholder yield 2.7% 2.8% 3.0%
Payout ratio (earnings) – – 92.0%
Payout ratio (FCF) – – 64.0%
Dividend growth (1Y) – – 6.9%
Dividend CAGR (3Y) – – 7.4%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusSOLVISRGABT
Forward P/E 12.8xFY2026 38.5xFY2026 19.1xFY2026
EPS, next fiscal year $6.93FY2026 $11.52FY2026 $5.69FY2026
EPS growth, next FY +13.4%FY2026 +29.0%FY2026 +10.5%FY2026
EPS growth, the year after +15.3% +4.5% +10.2%
Revenue, next fiscal year $7.71BFY2026 $11.62BFY2026 $52.99BFY2026
Revenue growth, next FY -7.3%FY2026 +15.5%FY2026 +19.5%FY2026
Revenue growth, the year after +5.8% +11.3% -2.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersSOLVISRGABT
Held by institutions 73.9% 86.2% 79.2%
Institutions holding 882 2,241 2,983
Change in shares held, QoQ -0.9% +4.6% +0.3%
Institutions buying 370 1,073 1,261
Institutions selling 286 879 1,379
Buyers to sellers 1.29 1.22 0.91

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

SOLVISRGABT
SOLV 1.00 0.35 0.37
ISRG 0.35 1.00 0.37
ABT 0.37 0.37 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, SOLV, ISRG and ABT?

Abbott Laboratories (ABT) is the largest by market capitalisation: Solventum (SOLV) $15.31B, Intuitive Surgical (ISRG) $154.57B, Abbott Laboratories (ABT) $188.33B.

Which stock is cheaper, SOLV, ISRG and ABT?

Abbott Laboratories (ABT) trades on the lowest price-to-earnings ratio (Solventum (SOLV) 98.1x, Intuitive Surgical (ISRG) 52.3x, Abbott Laboratories (ABT) 40.1x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Solventum (SOLV) 12.8x, Intuitive Surgical (ISRG) 38.5x, Abbott Laboratories (ABT) 19.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Intuitive Surgical (ISRG) grew revenue fastest over the trailing twelve months: Solventum (SOLV) -2.8%, Intuitive Surgical (ISRG) +20.5%, Abbott Laboratories (ABT) +10.0%.

Which company is more profitable?

Intuitive Surgical (ISRG) has the highest net margin (Solventum (SOLV) 1.9%, Intuitive Surgical (ISRG) 25.5%, Abbott Laboratories (ABT) 9.7%). On return on invested capital, Abbott Laboratories (ABT) leads (Solventum (SOLV) 4.2%, Abbott Laboratories (ABT) 5.7%).

Which stock has performed better?

Over the past year Solventum (SOLV) returned the most: Solventum (SOLV) +18.4%, Intuitive Surgical (ISRG) -21.6%, Abbott Laboratories (ABT) -16.0%. Over five years, Intuitive Surgical (ISRG) compounded fastest (Intuitive Surgical (ISRG) +4.6%/yr, Abbott Laboratories (ABT) -3.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Solventum (SOLV) 0.00%, Intuitive Surgical (ISRG) 0.00%, Abbott Laboratories (ABT) 0.02%. Solventum (SOLV) and Intuitive Surgical (ISRG) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Solventum (SOLV) 30.1%, Intuitive Surgical (ISRG) 36.1%, Abbott Laboratories (ABT) 28.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, SOLV, ISRG and ABT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Abbott Laboratories (ABT) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.